Skip to content
Rinvoq(upadacitinib)
Rinvoq (upadacitinib) is a small molecule pharmaceutical. Upadacitinib was first approved as Rinvoq on 2019-08-16. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, tyrosine-protein kinase JAK2, and non-receptor tyrosine-protein kinase TYK2.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Rinvoq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Upadacitinib
Tradename
Company
Number
Date
Products
RINVOQAbbVieN-211675 RX2019-08-16
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
rinvoqNew Drug Application2020-07-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
UPADACITINIB, RINVOQ, ABBVIE
2025-04-29I-888
2025-03-16I-886
2025-01-14I-883
2024-12-14I-880
2024-08-16NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Upadacitinib, Rinvoq, Abbvie
99510802036-10-17DS, DP
99634592036-10-17DP
102023932036-10-17DP
103440362036-10-17DP
105191642036-10-17DP
105501262036-10-17U-3298
105974002036-10-17U-3255
107308832036-10-17DP
109819232036-10-17DP
109819242036-10-17DP
109950952036-10-17U-3298
111865842036-10-17DP
111986972036-10-17DP
113651982036-10-17U-3275
115120922036-10-17U-3275, U-3371, U-3487
115249642036-10-17U-3371
115356242036-10-17U-3255
115356252036-10-17U-3298
115356262036-10-17U-3298
89626292031-01-15DPU-3255, U-3275, U-3341, U-3371
RE472212030-12-01DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AA: Selective immunosuppressants
L04AA44: Upadacitinib
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.91692118
Atopic dermatitisD003876EFO_0000274L201181213
Psoriatic arthritisD015535EFO_0003778L40.5213
SpondylarthritisD025241112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K50235
Ulcerative colitisD003093EFO_0000729K5133
Juvenile arthritisD001171EFO_0002609M08112
Takayasu arteritisD013625EFO_1001857M31.411
Giant cell arteritisD013700EFO_1001209M31.611
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic lupus erythematosusD008180EFO_0002690M3222
Hidradenitis suppurativaD017497L73.211
Ankylosing spondylitisD013167EFO_0003898M4511
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L4011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameUPADACITINIB
INNupadacitinib
Description
Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis and psoriatic arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. Upadacitinib works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Identifiers
PDB
CAS-ID1310726-60-3
RxCUI2196092
ChEMBL IDCHEMBL3622821
ChEBI ID
PubChem CID58557659
DrugBankDB15091
UNII ID4RA0KN46E0 (ChemIDplus, GSRS)
Target
Agency Approved
JAK1
JAK1
Organism
Homo sapiens
Gene name
JAK1
Gene synonyms
JAK1A, JAK1B
NCBI Gene ID
Protein name
tyrosine-protein kinase JAK1
Protein synonyms
JAK-1, Janus kinase 1
Uniprot ID
Mouse ortholog
Jak1 (16451)
tyrosine-protein kinase JAK1 (P52332)
Alternate
JAK3
JAK3
JAK2
JAK2
TYK2
TYK2
Organism
Homo sapiens
Gene name
JAK3
Gene synonyms
NCBI Gene ID
Protein name
tyrosine-protein kinase JAK3
Protein synonyms
JAK-3, Janus kinase 3, Janus kinase 3 (a protein tyrosine kinase, leukocyte), L-JAK, Leukocyte janus kinase
Uniprot ID
Mouse ortholog
Jak3 (16453)
tyrosine-protein kinase JAK3 (Q62137)
Variants
Clinical Variant
No data
Financial
Rinvoq - AbbVie
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,541 documents
View more details
Safety
Black-box Warning
Black-box warning for: Rinvoq
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
156 adverse events reported
View more details